Past Clinical Research Trials

GlaxoSmithKline: An open-lab, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for Subcutaneous administration of mepolizumab in severe eosinophilic asthma (GSK 204959)

May 2017

AstraZeneca: A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate fixed-dose combination relative to Umeclidinium/Vilanterol fixed-dose combination over 24 Weeks in patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO) (D5970C00002)

May 2017

Pearl Therapeutics: A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD (PT009002)

February 2017

AstraZeneca: A Randomised, Double-blind, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (GALATHEA)

May 2016

GlaxosmithKline: CTT116855 A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease

September 2015

GlaxoSmithKline: MEA117106 Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients

April 2014

GlaxoSmithKline: HZC102972, Multi-centre, randomized, double-blind, parallel-group study evaluating the effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder once daily compared with Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in subjects with Chronic Obstructive Pulmonary Disease (COPD)

November 2013

Novartis Pharmaceuticals Canada: A 12-week treatment, multi-center, randomized, double-blind, parallel-group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate / glycopyrronium bromide) in COPD patients with moderate to severe airflow limitation

July 2013

GlaxoSmithKline: A multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide Inhalation Powder (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks in subjects with COPD

April 2013

AstraZeneca: A Multicenter, Open-label, Functionality, Reliability and Performance Study of a Single-use Auto-injector with Home-administered Subcutaneous Benralizumab in Adult Patients with Severe Asthma (GRECO)

December 2016

AstraZeneca: A Multicenter, Open-label, Safety Extension Study with Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)

July 2016

GlaxoSmithKline: A clinical study to compare the protective effects of Fluticasone Furoate/Vilanterol 100/25mcg and Fluticasone Propionate 250mcg in asthmatics whose asthma worsens with exercise (201832)

June 2016

Novartis Pharmaceuticals Canada: A multi-centre, randomized, 52 week, double-blind, parallel-group active controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with active asthma (CQVM149B2302)

May 2016

GlaxoSmithKline: A multi-centre, open-label, 32-week study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100 mg subcutaneous (SC) (204471)

April 2016

GlaxoSmithKline: A Study for Identification and Description of Severe Asthma (IDEAL)

January 2015

AstraZeneca: A Multicentre, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Banralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroids Plus  Long-acting β2 Agonist (BORA)

January 2015

Novartis Pharmaceuticals Canada: Real-Life Effectiveness and safety of omalizumab in patients with severe allergic asthma: The Latin American and Canadian experience (RELIEF)

January 2015

AstraZeneca: A 52 week, double-blind, randomized, multi-centre, parallel-group, Phase III study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort® (budesonide/formoterol) Turbuhaler® 160/4 ug ‘as needed’ compared with terbutaline Turbuhaler® 0.4 mg ‘as needed’ and with Pulmicort® (budesonide) Turbuhaler® 200 ug twice daily plus terbutaline Turbuhaler® 0.4 mg ‘as needed’

December 2014

AstraZeneca: A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients with Uncontrolled Asthma (CALIMA)

November 2013

Amgen: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects with Inadequately Controlled Asthma and High Bronchodilator Reversibility

June 2013

Novartis Pharmaceuticals Canada: ASTERIX Asthma Exacerbations Reduced with Xolair: A Canadian, 12-Month, Multicentre, Open-Label Study Evaluating the Oral Corticosteroid Sparing Effect of Xolair (Omalizumab) Therapy in Inadequately-Controlled Moderate to Severe Allergic Asthma Patients.

Dec. 2012

Hoffman-La Roche Limited: ML29808 Inspiration Plus: A Prospective Observational Study to Evaluate Disease Course and Outcomes in Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Esbriet® (Pirfenidone) in Canada

October 2015